Diaryl SARMs

A potent SARM, S-4 (15), was identified which demonstrated rapid and complete oral absorption at low doses and reasonable elimination half-life (t1/2 = 2.6-5.3 h) in rats, suggesting compounds such as this would be excellent candidates for clinical development [88]. These successes focused our efforts on the diaryl propionanilide class of SARMs of which many have been published [89-92], Recent studies demonstrated that these SARMs improve skeletal (soleus) muscle strength, increase lean body mass (LBM), reduce body fat, prevent bone loss in rats, in addition to promising pharmacologic activity in animal models of benign prostatic hypertrophy and male fertility [92-95], Ostarine is the most advanced SARM clinical candidate and has demonstrated exciting data from its initial proof-of-concept phase II clinical trial. GTx reported in December 2006 the results of this clinical trial which was... 

---